Salivary dehydroepiandrosterone, but not cortisol, is associated with attention deficit hyperactivity disorder

World Journal of Biological Psychiatry

Volumn 12, Issue 2, 2011, Pages 99-109

  Wang, Liang Jen ^a,b   Huang, Yu Shu ^a,c   Hsiao, Chen Cheng ^a,c   Chiang, Yuan Lin ^a   Wu, Chih Ching ^c   Shang, Zong Yi ^a   Chen, Chih Ken ^a,c,d  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

ADHD; Continuous performance test; Cortisol; Dehydroepiandrosterone; Saliva

Indexed keywords

HYDROCORTISONE; PRASTERONE;

ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD PSYCHIATRY; CLINICAL ARTICLE; CONTINUOUS PERFORMANCE TEST; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; MALE; PERFORMANCE; PRESCHOOL CHILD; RATING SCALE; SALIVA LEVEL; SCHOOL CHILD; METABOLISM; NEUROPSYCHOLOGICAL TEST; SALIVA; TASK PERFORMANCE;

ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; CROSS-SECTIONAL STUDIES; DEHYDROEPIANDROSTERONE; FEMALE; HUMANS; HYDROCORTISONE; MALE; NEUROPSYCHOLOGICAL TESTS; SALIVA; TASK PERFORMANCE AND ANALYSIS;

EID: 79960106300     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622975.2010.512090     Document Type: Article

References (64)

1. American Psychiatric Association. 2000. Diagnostic and statistical manual of mental disorders. American Psychiatric Association: Washington D.C., USA.
2. Barkley RA. 1991. The ecological validity of laboratory and analogue assessment methods of ADHD symptoms. J Abnorm Child Psychol 19:149-178.
3. Baulieu EE. 1996. Dehydroepiandrosterone (DHEA): a fountain of youth? J Clin Endocrinol Metab 81:3147-3151.
4. Baulieu EE, Robel P. 1996. Dehydroepiandrosterone and dehydroepiandrosterone sulfate as neuroactive neurosteroids. J Endocrinol 150(Suppl):S221-239.
5. Biederman J, Faraone SV, Monuteaux MC, Plunkett EA, Gifford J, Spencer T. 2003. Growth defi cits and attention-defi cit/hyperactivity disorder revisited: impact of gender, development, and treatment. Pediatrics 111:1010-1016.
6. Biederman J, Mick E, Faraone SV. 2000. Age-dependent decline of symptoms of attention defi cit hyperactivity disorder: impact of remission defi nition and symptom type. Am J Psychiatry 157: 816-818. (Pubitemid 30249663)
7. Birmaher B, Heydl P. 2001. Biological studies in depressed children and adolescents. Int J Neuropsychopharmacol 4:149-157. (Pubitemid 32587383)
8. Brookes KJ, Hawi Z, Kirley A, Barry E, Gill M, Kent L. 2008. Association of the steroid sulfatase (STS) gene with attention defi cit hyperactivity disorder. Am J Med Genet B Neuropsychiatr Genet 147B:1531-1535.
9. Bussing R, Fernandez M, Harwood M, Wei H, Garvan CW, Eyberg SM, et al. 2008. Parent and teacher SNAP-IV ratings of attention defi cit hyperactivity disorder symptoms: psychometric properties and normative ratings from a school district sample. Assessment 15:317-328.
10. Cano B, de Oya M, Benavente M, Viturro E, de Oya I, Lopez-Simon L, et al. 2006. Dehydroepiandrosterone sulfate (DHEAS) distribution in Spanish prepuberal children: relationship with fasting plasma insulin concentrations and insulin resistance. Clin Chim Acta 366:163-167. (Pubitemid 43330977)
11. Compagnone NA, Mellon SH. 1998. Dehydroepiandrosterone: a potential signalling molecule for neocortical organization during development. Proc Natl Acad Sci USA 95:4678-4683. (Pubitemid 28207973)
12. Conners CK. 1985. The computerized continuous performance test. Psychopharmacol Bull 21:891-892. (Pubitemid 16177289)
13. Conners CK. 2004. Conners ' Continuous Performance Test II (CPTII) for Windows Technical Guide and Software Manual. MHS.
14. Davies W, Humby T, Kong W, Otter T, Burgoyne PS, Wilkinson LS. 2009. Converging pharmacological and genetic evidence indicates a role for steroid sulfatase in attention. Biol Psychiatry 66:360-367.
15. de Peretti E, Forest MG. 1978. Pattern of plasma dehydroepiandrosterone sulfate levels in humans from birth to adulthood: evidence for testicular production. J Clin Endocrinol Metab 47:572-577. (Pubitemid 9010409)
16. Epstein JN, Erkanli A, Conners CK, Klaric J, Costello JE, Angold A. 2003. Relations between Continuous Performance Test performance measures and ADHD behaviors. J Abnorm Child Psychol 31:543-554. (Pubitemid 37229132)
17. Freitag CM, Hanig S, Palmason H, Meyer J, Wust S, Seitz C. 2009. Cortisol awakening response in healthy children and children with ADHD: impact of comorbid disorders and psychosocial risk factors. Psychoneuroendocrinology 34:1019-1028.
18. Gallagher P, Leitch MM, Massey AE, McAllister-Williams RH, Young AH. 2006. Assessing cortisol and dehydroepiandrosterone (DHEA) in saliva: effects of collection method. J Psychopharmacol 20:643-649. (Pubitemid 44315863)
19. Gau SF, Soong WT. 1999. Psychiatric comorbidity of adolescents with sleep terrors or sleepwalking: a case-control study. Aust NZ J Psychiatry 33:734-739.
20. Gau SS, Chong MY, Chen TH, Cheng AT. 2005. A 3-year panel study of mental disorders among adolescents in Taiwan. Am J Psychiatry 162:1344-1350. (Pubitemid 40905586)
21. Gogtay N, Giedd J, Rapoport JL. 2002. Brain development in healthy, hyperactive, and psychotic children. Arch Neurol 59: 1244-1248. (Pubitemid 34856376)
22. Golubchik P, Lewis M, Maayan R, Sever J, Strous R, Weizman A. 2007. Neurosteroids in child and adolescent psychopathology. Eur Neuropsychopharmacol 17:157-164. (Pubitemid 44779197)
23. Gomez R. 2008. Item response theory analyses of the parent and teacher ratings of the DSM-IV ADHD rating scale. J Abnorm Child Psychol 36:865-885.
24. Goodyer IM, Park RJ, Netherton CM, Herbert J. 2001. Possible role of cortisol and dehydroepiandrosterone in human development and psychopathology. Br J Psychiatry 179:243-249. (Pubitemid 32844286)
25. Gurnell EM, Chatterjee VK. 2001. Dehydroepiandrosterone replacement therapy. Eur J Endocrinol 145:103-106. (Pubitemid 32707595)
26. Herbert J. 1998. Neurosteroids, brain damage, and mental illness. Exp Gerontol 33:713-727. (Pubitemid 29019329)
27. Hill JC, Schoener EP. 1996. Age-dependent decline of attention defi cit hyperactivity disorder. Am J Psychiatry 153:1143-1146. (Pubitemid 26299832)
28. Kaneko M, Hoshino Y, Hashimoto S, Okano T, Kumashiro H. 1993. Hypothalamic-pituitary-adrenal axis function in children with attention-defi cit hyperactivity disorder. J Autism Dev Disord 23:59-65. (Pubitemid 23117560)
29. Kariyawasam SH, Zaw F, Handley SL. 2002. Reduced salivary cortisol in children with comorbid Attention defi cit hyperactivity disorder and oppositional defi ant disorder. Neuro Endocrinol Lett 23:45-48. (Pubitemid 34192868)
30. Kaufman J, Birmaher B, Brent D, Rao U, Flynn C, Moreci P, et al. 1997. Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (KSADS-PL): initial reliability and validity data. J Am Acad Child Adolesc Psychiatry 36:980-988. (Pubitemid 27272932)
31. King JA, Barkley RA, Barrett S. 1998. Attention-defi cit hyperactivity disorder and the stress response. Biol Psychiatry 44:72-74. (Pubitemid 28305545)
32. Lee MS, Yang JW, Ko YH, Han C, Kim SH, Joe SH, et al. 2008. Effects of methylphenidate and bupropion on DHEA-S and cortisol plasma levels in attention-defi cit hyperactivity disorder. Child Psychiatry Hum Dev 39:201-209. (Pubitemid 351347942)
33. Liu YC LS, Shang CY, Lin CH, Tu CL, Gau SF. 2006. Norm of the Chinese Version of the Swanson, Nolan and Pelham, Version IV Scale for ADHD. Taiwanese J Psychiatry 20:290-304.
34. Maayan R, Yoran-Hegesh R, Strous R, Nechmad A, Averbuch E, Weizman A, et al. 2003. Three-month treatment course of methylphenidate increases plasma levels of dehydroepiandrosterone (DHEA) and dehydroepiandrosterone-sulfate (DHEA-S) in attention defi cit hyperactivity disorder. Neuropsychobiology 48:111-115. (Pubitemid 37340196)
35. Madaan V, Daughton J, Lubberstedt B, Mattai A, Vaughan BS, Kratochvil CJ. 2008. Assessing the efficacy of treatments for ADHD: overview of methodological issues. CNS Drugs 22:275-290. (Pubitemid 351367439)
36. MBH Gesellschaft F ü r Immunchemie Und Immunbiologie. 2007a. Luminescence Immunoassay for the quantitative determination of DHEA in human saliva and serum. IBL: Hamburg, Germany.
37. MBH Gesellschaft F ü r Immunchemie Und Immunbiologie 2007b. Luminescence Immunoassay for the quantitative determination of DHEA in human saliva and serum. IBL: Hamburg, Germany.
38. McAlonan GM, Cheung V, Chua SE, Oosterlaan J, Hung SF, Tang CP, et al. 2009. Age-related grey matter volume correlates of response inhibition and shifting in attention-defi cit hyperactivity disorder. Br J Psychiatry 194:123-129.
39. McBurnett K, Lahey BB, Rathouz PJ, Loeber R. 2000. Low salivary cortisol and persistent aggression in boys referred for disruptive behavior. Arch Gen Psychiatry 57:38-43. (Pubitemid 30035657)
40. Mick E, Biederman J, Prince J, Fischer MJ, Faraone SV. 2002. Impact of low birth weight on attention-defi cit hyperactivity disorder. J Dev Behav Pediatr 23:16-22. (Pubitemid 34213410)
41. Netherton C, Goodyer I, Tamplin A, Herbert J. 2004. Salivary cortisol and dehydroepiandrosterone in relation to puberty and gender. Psychoneuroendocrinology 29:125-140. (Pubitemid 37357174)
42. Nikolaidis A, Gray JR. 2009. ADHD and the DRD4 exon III 7-repeat polymorphism: an international meta-analysis. Soc Cogn Affect Neurosci.
43. Pajer K, Gardner W, Rubin RT, Perel J, Neal S. 2001. Decreased cortisol levels in adolescent girls with conduct disorder. Arch Gen Psychiatry 58:297-302. (Pubitemid 32209684)
44. Pastor PN, Reuben CA. 2005. Racial and ethnic differences in ADHD and LD in young school-age children: parental reports in the National Health Interview Survey. Public Health Rep 120:383-392. (Pubitemid 41206355)
45. Pearson DA, Santos CW, Casat CD, Lane DM, Jerger SW, Roache JD, et al. 2004. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD. J Am Acad Child Adolesc Psychiatry 43: 677-685. (Pubitemid 38858639)
46. Poulton A 2006. Growth and sexual maturation in children and adolescents with attention defi cit hyperactivity disorder. Curr Opin Pediatr 18:427-434. (Pubitemid 44259002)
47. Randazzo WT, Dockray S, Susman EJ. 2008. The stress response in adolescents with inattentive type ADHD symptoms. Child Psychiatry Hum Dev 39:27-38.
48. Riccio CA, Waldrop JJ, Reynolds CR, Lowe P. 2001. Effects of stimulants on the continuous performance test (CPT): implications for CPT use and interpretation. J Neuropsychiatry Clin Neurosci 13:326-335. (Pubitemid 32743710)
49. Sagvolden T, Sergeant JA. 1998. Attention defi cit/hyperactivity disorder-from brain dysfunctions to behaviour. Behav Brain Res 94:1-10. (Pubitemid 28352459)
50. Scerbo AS, Kolko DJ. 1994. Salivary testosterone and cortisol in disruptive children: relationship to aggressive, hyperactive, and internalizing behaviors. J Am Acad Child Adolesc Psychiatry 33:1174-1184. (Pubitemid 24296835)
51. Schulz KP, Halperin JM, Newcorn JH, Sharma V, Gabriel S. 1997. Plasma cortisol and aggression in boys with ADHD. J Am Acad Child Adolesc Psychiatry 36:605-609. (Pubitemid 27184067)
52. Shaw P, Eckstrand K, Sharp W, Blumenthal J, Lerch JP, Greenstein D, et al. 2007. Attention-defi cit/hyperactivity disorder is characterized by a delay in cortical maturation. Proc Natl Acad Sci USA 104:19649-19654.
53. Shin DW, Lee SH. 2007. Blunted hypothalamo-pituitary-adrenal axis reactivity is associated with the poor intelligence performance in children with attention-defi cit/hyperactivity disorder. Neuropediatrics 38:298-303. (Pubitemid 351751923)
54. Spencer TJ, Biederman J, Harding M, O'Donnell D, Faraone SV, Wilens TE 1996. Growth defi cits in ADHD children revisited: evidence for disorder-associated growth delays? J Am Acad Child Adolesc Psychiatry 35:1460-1469. (Pubitemid 26360931)
55. Spencer TJ, Biederman J, Mick E 2007. Attention-defi cit/hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. J Pediatr Psychol 32:631-642.
56. Strous RD, Spivak B, Yoran-Hegesh R, Maayan R, Averbuch E, Kotler M, et al. 2001. Analysis of neurosteroid levels in attention defi cit hyperactivity disorder. Int J Neuropsychopharmacol 4: 259-264. (Pubitemid 34101522)
57. Swanson JM, Kraemer HC, Hinshaw SP, Arnold LE, Conners CK, Abikoff HB, et al. 2001. Clinical relevance of the primary fi ndings of the MTA: success rates based on severity of ADHD and ODD symptoms at the end of treatment. J Am Acad Child Adolesc Psychiatry 40:168-179. (Pubitemid 32111020)
58. Szatmari P, Saigal S, Rosenbaum P, Campbell D, King S 1990. Psychiatric disorders at fi ve years among children with birthweights less than 1000g: a regional perspective. Dev Med Child Neurol 32:954-962. (Pubitemid 20340886)
59. Tang YP, Shimizu E, Dube GR, Rampon C, Kerchner GA, Zhuo M, et al. 1999. Genetic enhancement of learning and memory in mice. Nature 401:63-69.
60. Wolf OT, Kirschbaum C. 1999. Actions of dehydroepiandrosterone and its sulfate in the central nervous system: effects on cognition and emotion in animals and humans. Brain Res Brain Res Rev 30:264-288. (Pubitemid 29531488)
61. Wolf OT, Neumann O, Hellhammer DH, Geiben AC, Strasburger CJ, Dressendorfer RA, et al. 1997. Effects of a two-week physiological dehydroepiandrosterone substitution on cognitive performance and well-being in healthy elderly women and men. J Clin Endocrinol Metab 82:2363-2367. (Pubitemid 27287613)
62. Wolkowitz OM, Reus VI, Keebler A, Nelson N, Friedland M, Brizendine L, et al. 1999. Double-blind treatment of major depression with dehydroepiandrosterone. Am J Psychiatry 156:646-649. (Pubitemid 29162992)
63. Yang SJ, Shin DW, Noh KS, Stein MA. 2007. Cortisol is inversely correlated with aggression for those boys with attention defi cit hyperactivity disorder who retain their reactivity to stress. Psychiatry Res 153:55-60. (Pubitemid 47374821)
64. Zhang S, Faries DE, Vowles M, Michelson D. 2005. ADHD Rating Scale IV: psychometric properties from a multinational study as a clinician-administered instrument. Int J Methods Psychiatr Res 14:186-201. (Pubitemid 43013586)